Viera Sandecka

Brno, JM 62500, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.

Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.

Journal: International journal of molecular sciences

Published: April 25, 2026

High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.

High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.

Journal: HemaSphere

Published: March 26, 2026

Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors.

Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: October 30, 2025

Successful treatment of relapsed Waldenström's macroglobulinemia with proteasome inhibitors (bortezomib and subsequently ixazomib) in combination with rituximab and dexamethasone. A case report and review of the of proteasome inhibitors in Waldenström's….

Successful treatment of relapsed Waldenström's macroglobulinemia with proteasome inhibitors (bortezomib and subsequently ixazomib) in combination with rituximab and dexamethasone. A case report and review of the of proteasome inhibitors in Waldenström's….

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: January 08, 2025

The treatment combination of obinutuzumab, bendamustine and dexamethasone achieved a deeper response than the previous line of treatment in five patients with Waldenström's macroglobulinemia.

The treatment combination of obinutuzumab, bendamustine and dexamethasone achieved a deeper response than the previous line of treatment in five patients with Waldenström's macroglobulinemia.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: January 08, 2025

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.

Journal: Blood cancer journal

Published: June 15, 2024

Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis.

Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis.

Journal: European journal of haematology

Published: March 22, 2024

Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.

Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: June 23, 2023

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.

Journal: Blood cancer journal

Published: April 19, 2023

IgG4-related disease. Clinical manifestation differential diagnosis and recent International Diagnostic Criteria for IgG4-related disease.

IgG4-related disease. Clinical manifestation differential diagnosis and recent International Diagnostic Criteria for IgG4-related disease.

Journal: Vnitrni lekarstvi

Published: October 25, 2022

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.

Journal: Biomedicines

Published: September 10, 2022

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.

Journal: The Lancet. Haematology

Published: September 07, 2022

Showing 1-12 of 50

Last Updated: 09/26/2026